Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.9667
-0.0149-1.52%
Post-market: 0.9650-0.0017-0.18%19:34 EDT
Volume:288.31K
Turnover:290.67K
Market Cap:1.44M
PE:-0.01
High:1.06
Open:0.9998
Low:0.9500
Close:0.9816
52wk High:524.00
52wk Low:0.9199
Shares:1.49M
Float Shares:1.48M
Volume Ratio:0.08
T/O Rate:19.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-175.9200
EPS(LYR):-303.4772
ROE:-106.98%
ROA:-53.08%
PB:0.11
PE(LYR):0.00

Loading ...

Clearmind Medicine reports DSMB approves advancing Phase I/II AUD study

TIPRANKS
·
Aug 06

Clearmind Advances CMND-100 Alcohol Use Disorder Trial into Patient Testing After Phase I Safety Readout

Reuters
·
Aug 06

Clearmind Reaches Key Clinical Trial Milestone as Dsmb Unanimously Clears Progression in AUD Study

THOMSON REUTERS
·
Aug 06

Clearmind Signs LOI to Buy 51% Stake in EV Wireless Charging Firm for $2.5 Million

Reuters
·
Aug 03

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

THOMSON REUTERS
·
Aug 03

Clearmind Medicine - to Extend $1.50 Mln Loan at 4% Interest, Repayable in Two Years

THOMSON REUTERS
·
Aug 03

Clearmind Medicine - Deal Valued at $2.50 Mln for 51% Majority Stake

THOMSON REUTERS
·
Aug 03

Psychedelic: Clearmind reports safety findings for CMND-100

TIPRANKS
·
Jul 30

Clearmind Medicine announces safety results from Part A of CMND-100 tral

TIPRANKS
·
Jul 30

Clearmind Reports Positive Safety, Tolerability in Cmnd-100 Phase I/II Trial Part a Dose Escalation

Reuters
·
Jul 30

Clearmind Medicine - Study Achieves Primary Endpoint of Safety and Tolerability for Cmnd-100

THOMSON REUTERS
·
Jul 30

Clearmind Medicine - no Serious Adverse Events Observed in Part a of Cmnd-100 Trial

THOMSON REUTERS
·
Jul 30

Clearmind Announces Positive Safety Findings for Cmnd 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part a of Its FDA-Regulated Clinical Trial

THOMSON REUTERS
·
Jul 30

Clearmind Medicine - All 24 Participants Successfully Complete Treatment in Part a of Cmnd-100 Trial

THOMSON REUTERS
·
Jul 30

Clearmind Medicine completes Part A of CMND-100 trial

TIPRANKS
·
Jul 28

Clearmind Medicine Successfully Completes Part a of Its FDA Regulated Phase I/Ii Trial

Reuters
·
Jul 28

Clearmind Completes Part a Dosing in Phase I/II Cmnd-100 Trial for Alcohol Use Disorder

Reuters
·
Jul 28

Clearmind Targets Hong Kong Patent Protection to Support PTSD Drug Development Push

Reuters
·
Jul 20

Clearmind Medicine - Files Hong Kong Patent Application for Psychedelic Compounds Targeting Ptsd

THOMSON REUTERS
·
Jul 20

Clearmind reports positive retention results for intranasal formulation of MEAI

TIPRANKS
·
Jul 16